<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4767">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044873</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-015</org_study_id>
    <nct_id>NCT03044873</nct_id>
  </id_info>
  <brief_title>Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin</brief_title>
  <official_title>Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to assess the effect of coadministration of multiple doses of BMS-986165 on the
      systemic exposure of rosuvastatin in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum observed plasma concentration) of Rosuvastatin</measure>
    <time_frame>Up to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-T) (Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration) of Rosuvastatin</measure>
    <time_frame>Up to Day 13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(INF) (Area under the plasma concentration-time curve from time zero extrapolated to infinite time) of Rosuvastatin</measure>
    <time_frame>Up to Day 13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Deaths</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Serious Adverse Events</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Adverse Events</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events Leading to Discontinuation</measure>
    <time_frame>Up till 30 days after discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Inflammatory Diseases</condition>
  <arm_group>
    <arm_group_label>BMS 986165 and Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.</description>
    <arm_group_label>BMS 986165 and Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.</description>
    <arm_group_label>BMS 986165 and Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent

          2. Healthy male and female participants (not of childbearing potential) as determined by
             no clinically significant deviation from normal in medical history, physical exam,
             ECGs, and clinical laboratory determinations

          3. Subjects with body mass index of 18 to 32 kg/m2, inclusive.

          4. Women participants must have documented proof that they are not of childbearing
             potential.

          5. Men who are sexually active with WOCBP must agree to follow instructions for
             method(s) of highly effective contraception for the duration of study treatment(s)
             plus 5 half-lives of BMS-986165 (4 days) plus 90 days (duration of sperm turnover)
             for a total of 94 days of post BMS-986165 treatment. In addition, male participants
             must be willing to refrain from sperm donation during this time.

        Exclusion Criteria:

          1. History of allergy to BMS-986165, rosuvastatin, or related compounds, of myalgia or
             rhabdomyolysis while taking rosuvastatin or related compounds or any other drug
             allergy

          2. Any significant acute or chronic medical illness, active TB requiring treatment or
             documented latent TB within the previous 3 years, current or recent gastrointestinal
             disease, current or recent history of nausea, vomiting, constipation or irregular
             bowel movement

          3. History of chronic headaches, syncope, orthostatic instability, or recurrent
             dizziness, biliary disorders, drug-induced acne or rash, fibromyalgia, neutropenia or
             thrombocytopenia

          4. Smokers who currently smoke, recent drug or alcohol abuse, blood transfusion within 4
             weeks of study treatment administration, current skin findings that could interfere
             with the interpretation of study

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ppd Development, Llc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Thomas</last_name>
      <phone>512-747-4778</phone>
      <email>mark.thomas@ppdi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 22, 2017</lastchanged_date>
  <firstreceived_date>February 3, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
